Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS

Core Viewpoint - Analysts project Pfizer's quarterly earnings to be $0.48 per share, reflecting a 380% year-over-year increase, with revenues expected to reach$ 17.5 billion, a 22.8% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 3% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Pfizer Biopharma- Worldwide' revenues at $17.00 billion, indicating a year-over-year change of +22.6% [5]. - 'Revenues- Specialty Care- Vyndaqel family- Worldwide' are projected to reach$ 1.52 billion, reflecting a +57.9% year-over-year change [5]. - 'Revenues- Primary Care- Comirnaty direct sales and alliance revenues- Worldwide' are expected to be $3.27 billion, showing a -39.1% year-over-year change [6]. - 'Revenue- Primary Care- Nurtec ODT/Vydura- Worldwide' is projected at$ 384.55 million, indicating a +36.4% year-over-year change [6]. Regional Revenue Insights - 'Pfizer Biopharma- United States' is estimated at $9.29 billion, reflecting a +106.8% change from the year-ago quarter [7]. - 'Pfizer Biopharma- Total International' is projected to reach$ 7.71 billion, indicating a -17.7% change from the prior-year quarter [7]. - 'Revenue- Primary Care- Comirnaty direct sales and alliance revenues- Total International' is expected to be $2.43 billion, showing a -43.4% year-over-year change [8]. - 'Revenue- Primary Care- Paxlovid- Total International' is projected at$ 214.42 million, indicating an +88.1% year-over-year change [8]. Additional Revenue Metrics - 'Revenue- Primary Care- Nurtec ODT/Vydura- United States' is expected to be $358.64 million, reflecting a +30.4% change from the year-ago quarter [9]. - 'Revenue- Primary Care- Nurtec ODT/Vydura- Total International' is projected to reach$ 25.91 million, indicating a +270.1% year-over-year change [9]. - The average prediction for 'Revenue- Primary Care- United States' is $4.14 billion, reflecting a +426.4% year-over-year change [10]. - 'Revenue- Primary Care- Total International' is expected to be$ 4.50 billion, indicating a -27.4% change from the year-ago quarter [10]. Stock Performance - Pfizer shares have changed by +0.3% in the past month, compared to the Zacks S&P 500 composite's +1.2% move, with a Zacks Rank 3 (Hold) indicating expected performance closely aligned with the overall market [10].